OCX vs. CDIO, DRRX, TRIB, BMRA, ACHL, MYMD, ICCC, AWH, ABIO, and VNRX
Should you be buying OncoCyte stock or one of its competitors? The main competitors of OncoCyte include Cardio Diagnostics (CDIO), DURECT (DRRX), Trinity Biotech (TRIB), Biomerica (BMRA), Achilles Therapeutics (ACHL), MyMD Pharmaceuticals (MYMD), ImmuCell (ICCC), Aspira Women's Health (AWH), ARCA biopharma (ABIO), and VolitionRx (VNRX). These companies are all part of the "medical" sector.
Cardio Diagnostics (NASDAQ:CDIO) and OncoCyte (NASDAQ:OCX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, community ranking, earnings, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.
8.1% of Cardio Diagnostics shares are owned by institutional investors. Comparatively, 55.4% of OncoCyte shares are owned by institutional investors. 30.0% of Cardio Diagnostics shares are owned by company insiders. Comparatively, 1.9% of OncoCyte shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Cardio Diagnostics currently has a consensus price target of $1.35, suggesting a potential upside of 95.65%. OncoCyte has a consensus price target of $4.06, suggesting a potential upside of 63.81%. Given OncoCyte's stronger consensus rating and higher possible upside, research analysts plainly believe Cardio Diagnostics is more favorable than OncoCyte.
Cardio Diagnostics has higher earnings, but lower revenue than OncoCyte.
OncoCyte received 3 more outperform votes than Cardio Diagnostics when rated by MarketBeat users. However, 66.67% of users gave Cardio Diagnostics an outperform vote while only 8.33% of users gave OncoCyte an outperform vote.
In the previous week, OncoCyte had 4 more articles in the media than Cardio Diagnostics. MarketBeat recorded 6 mentions for OncoCyte and 2 mentions for Cardio Diagnostics. Cardio Diagnostics' average media sentiment score of 0.20 beat OncoCyte's score of -0.78 indicating that OncoCyte is being referred to more favorably in the news media.
Cardio Diagnostics has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -1,890.62%. Cardio Diagnostics' return on equity of -96.30% beat OncoCyte's return on equity.
Cardio Diagnostics has a beta of 5.03, indicating that its share price is 403% more volatile than the S&P 500. Comparatively, OncoCyte has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500.
Summary
Cardio Diagnostics beats OncoCyte on 8 of the 15 factors compared between the two stocks.
Get OncoCyte News Delivered to You Automatically
Sign up to receive the latest news and ratings for OCX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OCX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
OncoCyte Competitors List
Related Companies and Tools
